<DOC>
	<DOCNO>NCT00345761</DOCNO>
	<brief_summary>This study evaluate efficacy , safety pharmacokinetics capecitabine ( 2000 mg/m2/day mouth [ po ] , day 1 pm-day 15 every 3 week [ q3w ] ) , oxaliplatin ( 130 mg/m2 intravenously [ iv ] , day 1 q3w ) bevacizumab ( 7.5 mg/kg iv , day 1 q3w ) patient advance and/or metastatic colorectal cancer .</brief_summary>
	<brief_title>Clinical Study Capecitabine , Oxaliplatin Bevacizumab Colorectal Cancer</brief_title>
	<detailed_description>This study evaluate efficacy , safety pharmacokinetics Capecitabine ( 2000 mg/m2/day po , day 1 pm-day 15 q3w ) , Oxaliplatin ( 130 mg/m2 iv , day 1 q3w ) Bevacizumab ( 7.5 mg/kg iv , day 1 q3w ) patient advance and/or metastatic colorectal cancer .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult patient 2074 year age Histologically confirm colorectal cancer Metastatic and/or locally advanced colorectal cancer previously treat chemotherapy metastatic disease At least one measurable lesion accord RECIST Evidence clinically detectable ascites study treatment start Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start , anticipation need major surgical procedure course study ; fine needle aspiration within 7 day prior study treatment start . Evidence bleed diathesis coagulopathy Serious , nonhealing wound , ulcer , bone fracture Chronic , daily aspirin ( &gt; 325 mg/day ) , anticoagulant , medication know predispose gastrointestinal ulceration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Advanced and/or metastatic colorectal cancer</keyword>
</DOC>